Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge

Vaccine

Volumn 31, Issue 10, 2013, Pages 1385-1392

  Prabakaran, Mookkan ^a   Kolpe, Annasaheb B ^a   He, Fang ^a   Kwang, Jimmy ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

BacHA; Cellular immunity; Cross protective; H5N1; Oral vaccine; Pre pandemic

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 4; RECOMBINANT BACULOVIRAL VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACULOVIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADMINISTRATION ROUTE; FEMALE; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VIRUS A H5N1; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL; VIRUS STRAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACULOVIRIDAE; CROSS PROTECTION; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 84875808678     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.003     Document Type: Article

References (46)

1. Watanabe Y., Ibrahim M.S., Ellakany H.F., Kawashita N., Mizuike R., Hiramatsu H., et al. Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt. PLoS Pathog 2011, 7(5):e1002068.
2. http://www.who.int/influenza/human_animal_interface/EN_GIP_20120810CumulativeNumberH5N1cases.pdf.
3. Kost T.A., Condreay J.P. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol 2002, 20(4):173-180.
4. Hu Y.C. Baculoviral vectors for gene delivery: a review. Curr Gene Ther 2008, 8:54-65.
5. Volkman L.E., Goldsmith P.A. In vitro survey of autographa californica nuclear polyhedrosis virus interaction with nontarget vertebrate host cells. Appl Environ Microbiol 1983, 45:1085-1093.
6. Madhan S., Prabakaran M., Kwang J. Baculovirus as vaccine vectors. Curr Gene Ther 2010, 10:201-213.
7. Syed M.S., Kwang J. Oral vaccination of baculovirus-expressed VP28 displays enhanced protection against white spot syndrome virus in Penaeus monodon. PLoS ONE 2011, 6(11):e26428.
8. Xu X.G., Tong D.W., Wang Z.S., Zhang Q., Li Z.C., Zhang K., et al. Baculovirus virions displaying infectious bursal disease virus VP2 protein protect chickens against infectious bursal disease virus infection. Avian Dis 2011, 55(2):223-229.
9. Xu X.G., Wang Z.S., Zhang Q., Li Z.C., Zhao H.N., Li W., et al. Baculovirus surface display of E envelope glycoprotein of Japanese encephalitis virus and its immunogenicity of the displayed proteins in mouse and swine models. Vaccine 2011, 29:636-643.
10. Yoshida S., Kawasaki M., Hariguchi N., Hirota K., Matsumoto M. A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect Immun 2009, 77:1782-1789.
11. Prabakaran M., Madhan S., Prabhu N., Qiang J., Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J Virol 2010, 84(7):3201-3209.
12. Prabakaran M., He F., Meng T., Madhan S., Yunrui T., Jia Q., et al. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J Virol 2010, 84(22):11822-11830.
13. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005, 11:1515-1521.
14. Prabakaran M., Ho H.T., Prabhu N., Velumani S., Szyporta M., He F., et al. Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses. PLoS ONE 2009, 4:e4566.
15. Webster R.G., Kawaoka Y., Taylor J., Weinberg R., Paoletti E. Efficacy of nucleoprotein and hemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 1991, 9:303-308.
16. Centers for Disease Control and Prevention (U.S.), National Institutes of Health (U.S.) Biosafety in microbiological and biomedical laboratories 1999, U.S. Dept. of Health and Human Services Public Health Service Centers for Disease Control and Prevention; National Institutes of Health; For sale by the Supt. of Docs. U.S. G.P.O., Washington [Bethesda, MD] Washington D.C. 4th ed.
17. WHO Laboratory biosafety manual 2004, World Health Organization, Geneva. 3rd ed.
18. He F., Soejoedono R.D., Murtini S., Goutama M., Kwang J. Complementary monoclonal antibody-based dot ELISA for universal detection of H5 avian influenza virus. BMC Microbiol 2010, 10:330.
19. O'Reilly D.R., Miller L.K., Luckow V.A. Baculovirus expression vectors: a laboratory manual 1992, W.H. Freeman and Company, New York, NY.
20. Gallgher S., Winston S.E., Fuller S.A., Hurrell J.G.R. Immunoblotting and immunodetection. Current protocols in molecular biology 2004, 10.8.1-10.8.24. John Wiley&Sons. Inc., Newcastle, United Kingdom. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore (Eds.).
21. Rueda P., Fominaya J., Langeveld J.P., Bruschke C., Vela C., Casal J.I. Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles. Vaccine 2000, 19:726-734.
22. King D.J. Evaluation of different methods of inactivation of Newcastle disease virus and avian influenza virus in egg fluids and serum. Avian Dis 1991, 35:505-514.
23. Watarai S., Han M., Tana M., Kodama H. Antibody response in the intestinal tract of mice orally immunized with antigen associated with liposomes. J Vet Med Sci 1998, 60:1047-1050.
24. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3:e1501.
25. Suguitan A.L., McAuliffe J., Milis K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross protection in mice and ferrets. PLoS Med 2006, 3:e360.
26. Ibanez L.I., De Filette M., Hultberg A., Verrips T., Temperton N., Weiss R.A., et al. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J Infect Dis 2011, 203:1063-1072.
27. Tang X., Lu H., Ross T.M. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Vaccine 2010, 28:6821-6831.
28. Gao H., Wang Y., Li N., Peng W.P., Sun Y., Tong G.Z., et al. Efficient gene delivery into mammalian cells mediated by a recombinant baculovirus containing a whispovirus ie1 promoter, a novel shuttle promoter between insect cells and mammalian cells. J Biotechnol 2007, 131:138-143.
29. Chen C.Y., Liu H.J., Tsai C.P., Chung C.Y., Shih Y.S., Chang P.C., et al. Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms. Vaccine 2010, 28:7644-7651.
30. Blagborough A.M., Yoshida S., Sattabongkot J., Tsuboi T., Sinden R.E. Intranasal and intramuscular immunization with baculovirus dual expression system-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 2010, 28:6014-6020.
31. Meneses-Ruiz D.M., Laclette J.P., Aguilar-Díaz H., Hernández-Ruiz J., Luz-Madrigal A., Sampieri A., et al. Mucosal delivery of ACNPV baculovirus driving expression of the Gal-lectin LC3 fragment confers protection against amoebic liver abscess in hamster. Int J Biol Sci 2011, 7(9):1345-1356.
32. Kim S., Chang J. Baculovirus-based vaccine displaying respiratory syncytial virus glycoprotein induces protective immunity against RSV infection without vaccine-enhanced disease. Immune Netw 2012, 12:8-17.
33. Hu H., Voss J., Zhang G., Buchy P., Zuo T., Wang L., et al. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol 2012, 86:2978-2989.
34. Wang S., Fang L., Fan H., Jiang Y., Pan Y., Luo R., et al. Construction and immunogenicity of pseudotype baculovirus expressing GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine 2007, 25:8220-8227.
35. Li Y., Ye J., Cao S., Xiao S., Zhao Q., Liu X., et al. Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice. J Gen Med 2009, 11:57-65.
36. Fan H., Pan Y., Fang L., Wang D., Wang S., Jiang Y., et al. Construction and immunogenicity of recombinant pseudotype baculovirus expressing the capsid protein of porcine circovirus type 2 in mice. J Virol Methods 2008, 150:21-26.
37. Strauss R., Huser A., Ni S., Tuve S., Kiviat N., Sow P.S., et al. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein. Mol Ther 2007, 15:193-202.
38. Gronowski A.M., Hilbert D.M., Sheehan K.C., Garotta G., Schreiber R.D. Baculovirus stimulates antiviral effects in mammalian cells. J Virol 1999, 73(12):9944-9951.
39. Hervas-Stubbs S., Rueda P., Lopez L., Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunol 2007, 178:2361-2369.
40. Abe T., Hemmi H., Miyamoto H., Moriishi K., Tamura S., Takaku H., et al. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J Virol 2005, 79:2847-2858.
41. Abe T., Kaname Y., Wen X., Tani H., Moriishi K., Uematsu S., et al. Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. J Virol 2009, 83(15):7629-7640.
42. Bungener L., Geeraedts F., Ter Veer W., Medema J., Wilschut J., Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008, 26:2350-2359.
43. Graham M.B., Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 1997, 186:2063-2068.
44. Tamura S., Tanimoto T., Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58(4):195-207.
45. Tamura S., Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004, 57(6):236-247.
46. Shoji I., Aizaki H., Tani H., Ishii K., Chiba T., Saito I., et al. Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors. J Gen Virol 1997, 78:2657-2664.